News
LVZPF
4.350
NaN%
--
Livzon Subsidiary’s Ankylosing Spondylitis Drug Application Accepted by China’s NMPA
TipRanks · 06/01 15:06
Livzon Wins NMPA Approval for Biosimilar Fertility Drug
TipRanks · 06/01 15:04
Livzon Pharmaceutical Wins Shareholder Backing for All 2025 AGM and 2026 Class Meeting Resolutions
TipRanks · 05/29 14:05
Livzon Pharmaceutical Revamps Board and Affirms Director Independence
TipRanks · 05/29 14:03
Livzon Pharmaceutical Outlines Board and Committee Structure in Governance Update
TipRanks · 05/29 14:02
Livzon Pharmaceutical Declares Final 2025 Dividend and Sets Hong Kong Payout Details
TipRanks · 05/29 14:01
Livzon Secures Controlling Stake in Vietnam’s Imexpharm After Tender Offer Completion
TipRanks · 05/11 12:46
Livzon Gains Control of Vietnam’s Imexpharm in RMB 1.56 Billion Tender Offer
TipRanks · 04/29 13:21
Livzon Pharmaceutical Issues Revised Proxy Form for 2025 AGM
TipRanks · 04/24 13:39
Livzon Pharmaceutical Updates 2025 Final Dividend Timetable and Tax Details
TipRanks · 04/23 15:10
Livzon Pharmaceutical Sets 2025 AGM to Approve Results and Cash Dividend Plan
TipRanks · 04/23 14:41
Livzon Seeks Mandate for 10% H-Share Buyback to Bolster Capital Flexibility
TipRanks · 04/23 14:40
Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit Revenue
TipRanks · 04/23 14:11
Livzon Reshapes Board Succession Plan With Nomination of Vice President Liu Daping
TipRanks · 04/23 13:40
CICC Reaffirms Their Buy Rating on Livzon Pharmaceutical Group (LVZPF)
TipRanks · 04/15 02:03
Livzon Wins NMPA Nod for JP-1366 H. pylori Trial, Deepening GI Drug Portfolio
TipRanks · 04/10 10:07
Livzon Pharmaceutical Schedules Board Meeting to Review First-Quarter 2026 Results
TipRanks · 04/08 09:19
Livzon Clarifies 2025 Dividend Plan, Confirms RMB14.30 per 10 Shares
TipRanks · 03/26 12:16
Livzon Wins NMPA Nod to Trial Long-Acting Brexpiprazole for Schizophrenia
TipRanks · 03/26 11:41
Livzon Pharmaceutical Strengthens Board Committees With New Appointments
TipRanks · 03/24 13:41
More
Webull provides a variety of real-time LVZPF stock news. You can receive the latest news about Livzon Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About LVZPF
Livzon Pharmaceutical Group Inc is a China-based company principally engaged in the research, development, production and sale of pharmaceutical products. The Company's main businesses include chemical drug preparations, biological products, active pharmaceutical ingredients and intermediates, traditional Chinese medicine preparations, diagnostic reagents and equipment, commercial development and functional management. The Company's main products include Ilaprazole (Ilaprazole Enteric-Coated Tablets and Ilaprazole Sodium for Injection), a series of Bismuth Potassium Citrate products, Rabeprazole Sodium Enteric-Coated Capsules, Weisanlian (Bismuth Potassium Citrate Tablets/Tinidazole Tablets/Clarithromycin Tablets), Leuprorelin Acetate Microspheres for Injection, Urofollitropin for Injection, Menotropins for Injection, Voriconazole for Injection and others. The Company mainly operates its businesses in the domestic and overseas markets.